Abstract
The predominant product of cyclooxygenase (COX) activity in the colon, prostaglandin (PG) E2 promotes intestinal tumorigenesis. Expression of the PGE2 receptor EP4 is upregulated during colorectal carcinogenesis. Therefore, we investigated the role of elevated PGE2-EP4 receptor signalling in the protumorigenic activity of PGE2 by increasing EP4 receptor expression in HT-29 human colorectal cancer (CRC) cells (HT-29-EP4) by stable transfection. Elevated PGE2-induced EP4 receptor activity in HT-29 cells increased resistance to spontaneous apoptosis and promoted anchorage-independent growth, but had no effect on proliferation of HT-29-EP4 cells. EP4 receptor activation by PGE2 in HT-29-EP4 cells also led to development of fluid-filled cysts, which was associated with increased tight junction protein (occludin and zonula occludens-1) expression. Overexpression of the EP4 receptor in HT-29 cells led to basal EP4 receptor signalling in the absence of exogenous PGE2, which was explained by autocrine activity of endogenous, COX-2-derived PGE2 and constitutive, ligand-independent EP4 receptor activity. The predominant signalling pathway mediating antiapoptotic activity downstream of PGE2-EP4 receptor activation in HT-29-EP4 cells was elevation of cyclic adenosine monophosphate (cAMP) levels, which was associated with phosphorylation of cAMP-response element binding protein. EP4 receptor activation led to a small increase in phosphorylated extracellular signal-regulated kinase (ERK) 2 protein levels but inhibition of ERK phosphorylation did not abrogate the antiapoptotic activity of PGE2. However, PGE2-EP4 receptor signalling did not lead to trans-activation of the epidermal growth factor receptor in HT-29 cells. Inhibition of protumorigenic PGE2-EP4 receptor signalling represents a potential strategy for anti-CRC therapy that may avoid the toxicity associated with systemic COX inhibition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Adamson RH, Liu B, Nilson Fry G, Rubin LL, Curry FE . (1998). Microvascular permeability and number of tight junctions are modulated by cAMP. Am J Physiol Heart Circ Physiol 274: H1885–H1894.
Breyer RM, Bagdassarian CK, Myers SA, Breyer MD . (2001). Prostanoid receptors: subtypes and signalling. Annu Rev Pharmacol Toxicol 41: 661–690.
Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN . (2006). Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103: 1492–1497.
Buchanan FG, Wang D, Bargiacchi F, DuBois RN . (2003). Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451–35457.
Cahlin C, Gelin J, Andersson M, Lönroth C, Lundholm K . (2005). The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol 27: 913–923.
Cassano G, Gasparre G, Susca F, Lippe C, Guanti G . (2000). Effect of prostaglandin E2 on proliferation, Ca2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells. Cancer Lett 152: 217–222.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS . (2005). Prostaglandin E2 promotes colon cancer growth through a novel Gs-axin-β-catenin signalling axis. Science 310: 1504–1510.
Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D et al. (2006). Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66: 3106–3113.
Colucci R, Blandizzi C, Tanini M, Vassalle C, Breschi MC, Del Tacca M . (2005). Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. Br J Pharmacol 144: 338–348.
Desai S, Ashby B . (2001). Agonist-induced internalization and mitogen-activated protein kinase activation of the human prostaglandin EP4 receptor. FEBS Lett 501: 156–160.
Dye JF, Leach L, Clark P, Firth JA . (2001). Cyclic AMP and acidic fibroblast growth factor have opposing effects on tight and adherens junctions in microvascular endothelial cells in vitro. Microvasc Res 62: 94–113.
Elder DJE, Halton DE, Hague A, Paraskeva C . (1997). Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin Cancer Res 3: 1679–1683.
Fujino H, Regan JW . (2006). EP4 prostanoid receptor coupling to a pertussis toxin sensitive inhibitory G-protein. Mol Pharmacol 69: 13–18.
Fujino H, Salvi S, Regan RW . (2005). Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2 . Mol Pharmacol 68: 251–259.
Fujino H, West KA, Regan JW . (2002). Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signalling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2 . J Biol Chem 277: 2614–2619.
Fujino H, Xu W, Regan RW . (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278: 12151–12156.
Gardner SH, Hawcroft G, Hull MA . (2004). The effect of non-steroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 91: 153–163.
Grosser T, Fries S, FitzGerald GA . (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4–15.
Han C, Wu T . (2005). Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280: 24053–24063.
Han C, Michalopoulos GK, Wu T . (2006). Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207: 261–270.
Holla VR, Mann JR, Shi Q, DuBois RN . (2005). Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 281: 2676–2682.
Hoshino T, Tsutsumi S, Hwang H-J, Tsuchiya T, Mizushima T . (2003). Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 278: 12752–12758.
Hsi LC, Baek SJ, Eling TE . (2000). Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 256: 563–570.
Hull MA, Ko SCW, Hawcroft G . (2004). Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3: 1031–1039.
Hull MA . (2005). Cyclooxygenase-2: How good is it as a target for cancer chemoprevention? Eur J Cancer 41: 1854–1863.
Kato S, Aihara E, Yoshii K, Takeuchi K . (2005). Dual action of prostaglandin E2 on gastric acid secretion through different EP-receptor subtypes in the rat. Am J Physiol Gastrointest Liver Physiol 289: G64–G69.
Keese M, Magdeburg RJ, Herzog T, Hasenberg T, Offterdinger M, Pepperkok R et al. (2005). Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem 280: 27826–27831.
Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S . (1997). Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in chinese hamster ovary cells. Br J Pharmacol 122: 217–224.
Ko SCW, Chapple KS, Hawcroft G, Coletta PL, Markham AF, Hull MA . (2002). Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene 21: 7175–7186.
Krause W, DuBois RN . (2001). Eicosanoids and the large intestine. Prostagl and Other Lipid Mediator 61: 145–161.
Ma X, Kundu N, Rifat S, Walser T, Fulton AM . (2006). Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 66: 2923–2927.
Mayr B, Montminy M . (2001). Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature Rev Mol Cell Biol 2: 599–609.
Mendez M, LaPointe MC . (2005). PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol 288: H2111–H2117.
Misra UK, Pizzo SV . (2005). Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling. J Biol Chem 280: 38276–38289.
Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T et al. (2002). Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62: 28–32.
Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA . (2004). Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem 279: 26176–26183.
Nishihara H, Kizaka-Kondoh S, Insel PA, Eckmann L . (2003). Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 100: 8921–8926.
Ophir I, Cohen E, Ben Shaul Y . (1995). Apical polarity in human colon carcinoma cell lines. Tissue Cell 27: 659–666.
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS . (2002). Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med 8: 289–293.
Pavlovic S, Du B, Sakamoto K, Khan KMF, Natarajan C, Breyer RM et al. (2006). Targeting PGE2 receptors as an alternative strategy to block COX-2-dependent extracellular matrix-induced MMP-9 expression by macrophages. J Biol Chem 281: 3321–3328.
Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM et al. (2004). Colon carcinoma cell growth is associated with prostaglandin E2-EP4 receptor-evoked ERK activation. J Biol Chem 279: 29797–29804.
Regan RW . (2003). EP2 and EP4 prostanoid receptor signalling. Life Sci 74: 143–153.
Sales KT, Maudsley S, Jabbour HN . (2004). Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3′, 5′-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signalling pathways. Mol Endocrinol 18: 1533–1545.
Seifert R, Wenzel-Seifert K . (2002). Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366: 381–416.
Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN . (2000). Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275: 33951–33956.
Sheng H, Shao J, Washington MK, DuBois RN . (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075–18081.
Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T et al. (2004). Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53: 1151–1158.
Smith M-L, Hawcroft G, Hull MA . (2000). The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36: 664–674.
Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN . (2005). Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65: 1822–1829.
Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B et al. (2004). Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 6: 285–295.
Wright CW, Duckett CS . (2005). Reawakening the cellular death program in neoplasia through therapeutic blockade of IAP function. J Clin Invest 115: 2673–2678.
Acknowledgements
We thank Dr John Regan for the kind gift of the pCEP4-EP4 plasmid. Dr Ewan Morrison gave valuable help with time-lapse microscopy. Dr Valerie Speirs provided human EP4 receptor primers for real-time PCR. This work was funded by the Association for International Cancer Research. MA Hull is a Medical Research Council (UK) Senior Clinical Fellow, work in his laboratory is also funded by the World Cancer Research Fund and Yorkshire Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Hawcroft, G., Ko, C. & Hull, M. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 26, 3006–3019 (2007). https://doi.org/10.1038/sj.onc.1210113
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210113
Keywords
This article is cited by
-
Association of PTGER4 and PRKAA1 genetic polymorphisms with gastric cancer
BMC Medical Genomics (2023)
-
Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress
Scientific Reports (2019)
-
Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis
Scientific Reports (2017)
-
ω-3 Polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis
Phytochemistry Reviews (2014)
-
Cyclooxygenase-2 inhibition by novel Bisaryl imidazolyl imidazole derivatives increases Bax/Bcl-2 ratio and upregulates Caspase-3 gene expression in Caco-2 colorectal cancer cell line
Genes & Genomics (2012)